Chemistry: molecular biology and microbiology – Spore forming or isolating process
Reexamination Certificate
1999-11-12
2003-04-22
Jones, W. Gary (Department: 1634)
Chemistry: molecular biology and microbiology
Spore forming or isolating process
C435S242000, C436S501000, C536S022100
Reexamination Certificate
active
06551812
ABSTRACT:
FIELD OF THE INVENTION
The invention relates generally to the identification of agents for treating pathophysiologies associated with peroxisomal proliferator activated receptor-&agr; (PPAR&agr;), and of identifying ligands for PPAR&agr;, and of identifying agents for treating these pathophysiologies. More particularly, the invention relates to methods of diagnosing these pathophysiologies, and of identifying agents for treating these pathophysiologies, using nucleic acids whose expression changes following addition to cells of a ligand for PPAR&agr;.
BACKGROUND OF THE INVENTION
Elevated low-density lipoprotein (LDL) cholesterol has long been recognized as an independent risk factor for the development of coronary artery disease and subsequent myocardial ischemia and infarction. There is also growing evidence that elevated triglycerides may also present a significant independent risk factor for development of coronary heart disease.
Increased triglyceride-rich lipoprotein remnants play a central role in increased atherosclerosis in several dyslipoproteinemias. Elevated triglycerides associated with low HDL is a frequent genetic dyslipoproteinemia in patients with established cardiovascular disease.
The fibrate class of lipid lowering agents have been demonstrated effective in managing coronary artery disease. Fibrates include the marketed drugs clofibrate (Atromid), Gemfibrozil (Lopid), Fenofibrate (Lipidil), ciprofibrate (Lipanor) and the experimental compound bezafibrate, These fibrates have been characterized as peroxisome proliferators based upon their ability to increase peroxisome number and activity in rodent model systems. Molecular characterization of the peroxisome proliferator activated receptor &agr; (PPAR&agr;), and subsequent pharmacological analysis of the fibrate compounds has demonstrated that these compounds are ligands of the PPAR&agr;. PPAR&agr; is expressed in the liver, kidney and heart. Natural ligands for the receptor include C16-C20 polyunsaturated monocarboxylic fatty acids (PUFA).
The lipid lowering effects of fibrates are directly mediated through PPAR&agr;. These receptors are members of the nuclear receptor superfamily of ligand-dependent transcription factors. Three subtypes of mammalian PPAR's have been characterized: -alpha, -gamma, -delta. Members of the PPAR family exert their effect on transcriptional regulation through heterodimerization of ligand-bound PPAR receptors with the retinoid X receptor (RXR). These activated receptors bind to PPAR response elements (PPRE's) in DNA to initiate a transcriptional response.
Peroxisomes, a class of subecclular organelles with which PPAR&agr; is associated, are enclosed by a single-layered membrane. Currently, more than 50 metabolically relevant enzymatic activities have been characterized within the peroxisome. These include &bgr;-oxidation of long-chain fatty acids and derivatives (dicarboxylic acids, prostanoids, some xenobiotics and the side chain of cholesterol), fatty acid elongation, the hydrolysis of acyl-CoA's and their conversion to acylcamitines, biosynthesis of ether glycerolipids, cholesterol and dolichols, the catabolism of purines, polyamines and amino acids and the metabolism of reactive oxygen species. Various in vivo and in vitro drug-dosing models have each associated one or two genes from these pathways with PPAR&agr; ligand activity. However, a comprehensive analysis of PPAR&agr; ligand-mediated activity has not been described.
SUMMARY OF THE INVENTION
The present invention is based in part on the discovery of changes in expression patterns of multiple nucleic acid sequences in rodent liver cells following exposure to a ligand for a PPAR&agr;. The nucleic acid sequences whose expression changes include nucleic acid sequences encoding previously described polypeptides, as well as heretofore undescribed nucleic acid sequences. Expression of a subset of the sequences increased in liver cells following addition of the PPAR&agr; ligand, while expression of other sequences decreased following exposure to the ligand.
Based in part on the identification of these PPAR&agr; ligand responsive nucleic acid sequences, the invention provides screening methods based on nucleic acid sequences responsive to PPAR&agr; ligands. Also provided are methods for diagnosing or assessing conditions associated with PPAR&agr; metabolism using genes differentially expressed in response to PPAR&agr; ligands, as well as methods of treating adrenoleukodystrophy using PPAR&agr; ligands. In other aspects, the invention provides nucleic acid collections for identifying agents and pathologies associated with PPAR&agr; ligand responsive nucleic acid sequences. The invention additionally provides substrate arrays for identifying agents and pathologies associated with PPAR&agr; ligand responsive nucleic acid sequences, as well as single nucleotide polymorphisms associated with PPAR&agr; ligand responsive genes. The PPAR&agr;-mediated disorders described herein can include, e.g, the pathophysiology is selected from the group consisting of: adrenoleukodystrophy; hyperlipidemia; peroxisomal disorders; dyslipidemia; hypertriglyceridemia; coronary artery disease; myocardial ischemia and infarction; and disorders associated with lipid metabolism, fatty acid metabolism, ketogenesis, microsomal-oxidation, and fatty acid-oxidation.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description and claims.
REFERENCES:
patent: 5356807 (1994-10-01), Blass et al.
patent: WO 96/01317 (1996-01-01), None
patent: WO 98/27994 (1998-07-01), None
patent: WO 99/05161 (1999-02-01), None
International Search Report, PCT/US99/26737.
Aoyama et al. “Altered Constituitive Expression of Fatty Acid-Metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator Activated Receptor Alpha”J. Biol. Chem.273 (10):5678-5684 (1998).
Ouali F. et al. “Dietary lipis regulate beta-oxidation enzyme gene expression in developing rat kidney”Am. J. Physiology275 (5):F777-F784. (1988).
Brown, P.J. et al. “A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR alpha agonist with potent lipid-lowering activity”J. Med. Chem.42(19):3785-3788 (1999).
Ellinghaus P. et al. “Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPAR alpha) in sterol carrier protein 2-/sterol carrier protein x-deficient mice”J. Biol. Chem.274(5):2766-2772 (1999).
(1998). “New warnings issued for bromfenac, astemizole [news].”Am J Health Syst Pharm55(6): 526.
Aldridge, T. C., J. D. Tugwood, et al. (1995). “Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription.”Biochem J306(Pt 2): 473-9.
Alvares, K., A. Carrillo, et al. (1990). “Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family.”Proc Natl Acad Sci U S A87(14): 5293-7.
Assimacopoulos-Jeannet, F., M. Moinat, et al. (1991). “Effects of a peroxisome proliferator on beta-oxidation and overall energy balance in obese (fa/fa) rats.”Am J Physiol260(2 Pt 2): R278-83.
Austin, E. W., J. R. Okita, et al. (1995). “Modification of lipoperoxidative effects of dichloracetate and trichloroacetate is associated with peroxisome proliferation.”Toxicology97(1-3): 59-69.
Baes, M., H. Castelein, et al. (1995). “Antagonism of COUP-TF and PPAR alp
Chakrabarti Arun
CuraGen Corporation
Elrifi Ivor R.
Jones W. Gary
Kozakiewicz Cynthia
LandOfFree
Compositions and methods relating to the peroxisomal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods relating to the peroxisomal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods relating to the peroxisomal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3041435